Role of cytidine deaminase as a parameter for anticancer drug sensitivity in the tailor-made therapy

胞苷脱氨酶作为抗癌药物敏感性参数在定制治疗中的作用

基本信息

  • 批准号:
    13671673
  • 负责人:
  • 金额:
    $ 2.24万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2001
  • 资助国家:
    日本
  • 起止时间:
    2001 至 2002
  • 项目状态:
    已结题

项目摘要

Objctive: Cytidine deaminase (CDD) is involved in the metabolism of new pyrimidine analogues, capecitabine (N^4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine ) and gemcitabine (2',2'-difluorodeoxycytidine: dFdC). The purpose of present study is to directly examine the role of CDD in tumor cells themselves in mediating the sensitivity to capecitabine as compared with gemcitabine. Methods: Human bladder cancer cell line T24 was transfected with human CDD2 cDNA by the lipofectin method. Results: Transfection of CDD2 cDNA did not change the levels of thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), and thymidylate synthase (TS) but increased the CDD activity significantly (p<0.01). Forced expression of CCD made T24 sensitive to 5'-deoxy-5-fluorocyidine (5'DFCR) in vitro and capecitabine in vivo, but resistant to gemitabine both in vitro and in vivo. Tetrahydrouridine (THU), a specific CDD inhibitor, abrogated the changes in the in-vitro sensitivity to 5'DFCR and gemcitabine by transfection of CDD2 cDNA. Transfection of CDD2 cDNA resulted in significant increase in cellular 5-fluorouracil (5FU) level (p<0.01) and inhibition of TS activity (p<0.01) after treatment with 5'DFCR in vitro. Conclusion: The present study clearly showed direct evidence for the contribution of CDD in tumor cells themselves to the sensitivities to capecitabine and gemcitabine.
目的:胞苷脱氨酶参与新的嘧啶类似物卡培他滨((N^4-pentyloxycarbonyl-5‘-deoxy-5-fluorocytidine)和吉西他滨(2’,2‘-二氟脱氧胞苷)的代谢。本研究的目的是与吉西他滨比较,直接研究CDD在肿瘤细胞自身在调节对卡培他滨敏感性中的作用。方法:用脂质体转染法将人CDD2基因导入人膀胱癌T24细胞。结果:CDD2基因不影响胸苷磷酸化酶(TP)、二氢嘧啶脱氢酶(DPD)和胸苷合成酶(TS)的活性,但显著提高CDD活性(p&lt;0.01)。强制表达CD使T24在体外对5‘-脱氧-5-氟胞苷(5’-DFCR)敏感,在体内对卡培他滨敏感,但在体内和体外均对吉他滨耐药。CDD特异性抑制剂四氢尿苷(清华)可阻断CDD2基因对5‘DFCR和吉西他滨体外敏感性的影响。5‘-DFCR处理细胞后,CDD2基因的表达水平显著升高(p&lt;0.01),TS活性显著降低(p&lt;0.01)。结论:本研究清楚地表明肿瘤细胞中的CDD对卡培他滨和吉西他滨的敏感性有直接的贡献。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tatsio Morita: "Forced expression of cytidine deaminase confers sensitivity to capecitabine"ONCOLOGY, in press.
Tatsio Morita:“胞苷脱氨酶的强制表达赋予对卡培他滨的敏感性”《肿瘤学》,出版中。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MORITA Tatsuo其他文献

MORITA Tatsuo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MORITA Tatsuo', 18)}}的其他基金

Heterogeneity of bladder cancer : relation to mutations of oncogenes and antioncogene
膀胱癌的异质性:与癌基因和抑癌基因突变的关系
  • 批准号:
    08671837
  • 财政年份:
    1996
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment and characterization of T cell clones from autologous tumor-specific T cells in renal cell carcinoma
肾细胞癌自体肿瘤特异性 T 细胞 T 细胞克隆的建立和表征
  • 批准号:
    05671333
  • 财政年份:
    1993
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Examinations of anticancer drug sensitivity of pancreatic cancer using metabolomics from saliva and urine and plasma
利用唾液、尿液和血浆的代谢组学检查胰腺癌的抗癌药物敏感性
  • 批准号:
    17K08427
  • 财政年份:
    2017
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic research of cancer therapy by improving anticancer drug sensitivity through tumor vascular remodeling
通过肿瘤血管重塑提高抗癌药物敏感性的癌症治疗基础研究
  • 批准号:
    17K08602
  • 财政年份:
    2017
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Notch signaling and anticancer drug sensitivity in oral squamous cell carcinoma
口腔鳞状细胞癌中的Notch信号传导和抗癌药物敏感性
  • 批准号:
    8981737
  • 财政年份:
    2015
  • 资助金额:
    $ 2.24万
  • 项目类别:
Development of the anticancer drug sensitivity testing and elucidation of the resistance mechanism for oral cancer using new cultural method CTOS
利用新培养方法CTOS开发抗癌药敏试验并阐明口腔癌耐药机制
  • 批准号:
    25463110
  • 财政年份:
    2013
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
DNA mismatch repair gene analysis predicts the response to anticancer drug sensitivity in gastrointestinal cancers for tailored therapy.
DNA 错配修复基因分析可预测胃肠道癌症对抗癌药物敏感性的反应,以进行定制治疗。
  • 批准号:
    24390321
  • 财政年份:
    2012
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The significance of transcription-reverse transcription concerted reaction method for detecting circulating tumor cells in patients with colorectal cancer and for anticancer drug sensitivity marker.
转录-逆转录协同反应方法检测结直肠癌患者循环肿瘤细胞及抗癌药物敏感性标志物的意义
  • 批准号:
    23591965
  • 财政年份:
    2011
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Prediction of sensitivity and tolerance of anticancer drug for biliary tract cancer by applying a combination of targeted proteomics and metabolomic analyses.
通过应用靶向蛋白质组学和代谢组学分析相结合来预测抗癌药物对胆道癌的敏感性和耐受性。
  • 批准号:
    22390254
  • 财政年份:
    2010
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Identification of Genomic Locus Related to Sensitivity Against Anticancer Drug and Predisposition of Pancreatic Cancer Using Comprehensive Analysis
综合分析鉴定与抗癌药物敏感性和胰腺癌易感性相关的基因组位点
  • 批准号:
    19590751
  • 财政年份:
    2007
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Prediction of lung cancer prognosis, and anticancer drug sensitivity by diversified clinical-gene set screening through microarray analysis, mutation, and aberrant methylation
通过微阵列分析、突变和异常甲基化进行多样化临床基因组筛选,预测肺癌预后和抗癌药物敏感性
  • 批准号:
    18591540
  • 财政年份:
    2006
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study of the inhibitory effects on malignant progression and anticancer drug sensitivity of human squamous cell carcinoma by intensifying cell to cell communication
通过加强细胞间通讯抑制人鳞状细胞癌恶性进展和抗癌药物敏感性的研究
  • 批准号:
    17592100
  • 财政年份:
    2005
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了